Copay Coupons, PAPs Defray Nearly $11 Mil. In Specialty Drug Costs In PBM Study
This article was originally published in The Pink Sheet Daily
Prime Therapeutics study tracks use of cost-sharing assistance programs by 28,800 members through analysis of 125,000 specialty drug claims across multiple categories filed during the first six months of 2013.
You may also be interested in...
Letter from department’s general counsel responds to request from the company for a pre-enforcement advisory opinion. Despite the letter, Lilly maintains its ‘limited distribution program is fully consistent with applicable laws and regulations.’
Center for American Progress suggests pricing reforms for the 'next Administration' in lieu of legislation.
Effectiveness can be evaluated more quickly because researchers won’t have to wait for the second dose, company executive notes during briefing on the launch of the Phase III study.